Towards Healthcare
Advanced Liver Cancer Market Hits USD 2.97 Billion in 2025

Advanced Liver Cancer Market 2025 AI and Liquid Biopsy Innovations Driving Future Diagnostics

Based on market forecasts, the global advanced liver cancer market, projected at USD 2.65 billion in 2024, is expected to reach USD 8.2 billion by 2034, growing at a CAGR of 11.94% over the forecast period. Emergence of diverse severe liver issues and rising demand for advanced therapies are encouraging the global market expansion. The highly advanced healthcare systems and the presence of leading companies are impacting North America’s market dominance.

  • Insight Code: 5953
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: August 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

The advanced liver cancer market is projected to reach USD 8.2 billion by 2034, growing at a CAGR of 11.94% from 2024 to 2034.

North America is currently leading the advanced liver cancer market due to the presence of major market leaders and increased healthcare expenses.

The advanced liver cancer market includes seven segments, such as by cancer type, by treatment type, by drug class, by end user, by route of administration, by diagnosis and monitoring method, and by region.

Symptoms of advanced liver cancer include jaundice, abdominal pain, fatigue, digestive issues, loss of appetite, unintentional weight loss, and abdominal swelling. 

Advanced liver cancer is diagnosed by a combination of blood tests (including liver function tests), imaging scans (like CT or MRI), and biopsies. 

NIH, NCI, HEALTHDIRECT, ACS, MEDLINEPLUS, CDC, US FDA, GOV.UK